Psychedelics Chapter 4 - Psychedelic Regulations & The Controlled Substances Act

5 schedules of drugs - where do Psychedelics fall?

• Schedule I: Highest abuse potential; NO accepted medical utility; high health risk. No prescriptions permitted; off-label clinical prescribing is strictly illegal. Examples: Psilocybin, LSD, Mescaline, MDMA, Heroin, Cannabis.

4. The Schedule I Research 'Catch-22' & Risk Context

• The Administrative Impasse: By statutory definition, Schedule I drugs have 'no accepted medical use.' However, imposing Schedule I status creates severe bureaucratic and financial barriers to running randomized controlled trials. Regulators subsequently cite the lack of large-scale clinical trials to justify maintaining Schedule I status, locking research in a cyclical Catch-22 for decades.

cattch 22

Controlled vs. Uncontrolled Risk: Adverse public health hazards disproportionately manifest in unregulated, illicit settings lacking medical screening, precise chemical dosing, and psychological support. Conversely, in rigorous clinical environments with trained therapists and rescue protocols, classic psychedelics consistently demonstrate high tolerability and low physiological toxicity.

Federal Expenditure:

• Over $1 Trillion expended federally on drug prohibition enforcement since 1971.

State Mass Incarceration:

•  US states spend approximately $182 billion annually to incarcerate nearly 2 million citizens for drug offenses, causing disproportionate generational harm to urban and minority communities.

Psychiatric Freeze:

• Flourishing psychiatric research from the 1950s and 1960s exploring psychedelic-assisted psychotherapy was dismantled and suppressed for more than thirty years.

Statutory Authority:

• Authorized under the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 to expedite development of drugs treating serious or life-threatening conditions.

Designation Standard:

• Requires preliminary clinical evidence demonstrating substantial improvement / meaningful superiority over existing standard of care therapies on clinically significant endpoints.

Designated Psychedelics:

• Psilocybin (for Treatment-Resistant Depression and Major Depressive Disorder), MDMA (for PTSD), and LSD (for generalized anxiety).

Legal Distinction:

• Breakthrough Therapy status provides intensive FDA guidance and rolling review, but does NOT alter Schedule I federal criminal classification prior to formal New Drug Application (NDA) approval.

Decriminalization:

• Removes criminal arrest and incarceration for personal possession below designated quantity thresholds; enforces civil sanctions (fines, citations, or health screening referrals); maintains criminal prohibition on commercial sales, manufacture, and unregulated trade.

Legalization

• Permits lawful adult possession, use, and regulated retail or supervised commerce; creates state licensing frameworks (e.g., Oregon Measure 109, Colorado Healing Centers); institutes quality control, mandatory testing, dosage caps, professional facilitation rules, and state taxation.

Ancient Sacramental Heritage

• Archaeological evidence demonstrates indigenous ceremonial use of peyote (Lophophora williamsii, containing mescaline) in North America dating back to at least 4000 BCE.

Native American Church (NAC, 1918):

• Formally incorporated in 1918 to protect sacramental peyote rituals from state anti-drug suppression.

AIRFA Amendments (1978 & 1994):

• The American Indian Religious Freedom Act Amendments explicitly protect the traditional, religious, and sacramental use of peyote by Native American Church members nationwide, overriding Schedule I prohibitions.

RFRA & DEA Guidance

• The Religious Freedom Restoration Act (1993) requires federal drug enforcement to provide exemptions when enforcement substantially burdens sincere religious practice without demonstrating a compelling, least restrictive state interest; clarified in 2020 DEA guidance.

2019:

• Denver, Colorado becomes first US city to decriminalize psilocybin; Oakland, California decriminalizes all entheogenic plants and fungi.

2020:

• Santa Cruz (CA) and Ann Arbor (MI) decriminalize; Oregon voters approve historic Ballot Measure 109 (licensing supervised adult psilocybin services).

2021:

• Seattle (WA), Detroit (MI), and multiple Massachusetts municipalities enact entheogenic plant decriminalization.

2022-2024:

• San Francisco (CA) and Minneapolis (MN) pass decriminalization resolutions; Colorado enacts natural medicine regulations for licensed healing centers.